Novo Holdings
About Novo Holdings
Novo Holdings is a holding and investment company that manages the assets and wealth of the Novo Nordisk Foundation. It acts as the controlling shareholder of Novo Nordisk and Novo Group companies, investing across life sciences and a diversified portfolio including equities, real estate, infrastructure, and private equity. The company operates from offices in Copenhagen, London, San Francisco, Boston, Singapore, and Shanghai, with a focus on long-term returns to support health and sustainability outcomes. Novo Holdings emphasizes responsible investments and aims to improve people’s health and the sustainability of society and the planet.
Recent News
TandemAI Closes $22M Series A Extension Round
Is Pharma Missing the Boat on Diagnostics?
Terremoto Wins $108m in Series C to Drive Cancer and Rare Disease Programmes
GSK Functionally Cures Hepatitis B, Lilly's $3.8B Vaccine Pivot, and Base Editing Holds for 18 Months – This Week in Biotech #102
Macrocycles: Big Is the New Beautiful
Salesforce vs Veeva - the Game's Afoot and the Life Sciences Battleground Is Hotting Up!
VC Firm 2150 Raises €210M Fund to Solve Cities’ Climate Challenges
MSD-Backed Ray Locks in $125m to Back Eye Drug Pipeline
Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials
PCI Adds US Sterile Fill/Finish Capabilities Through $1B Global Expansion Drive
EU Moves Forward on $5.8B Scale-Up Fund to Keep Startups From Leaving
Danish Foodtech REDUCED Brings Series A to €12 Million to Support Industrial Rollout of Clean-Label Savoury Ingredients
Novonesis & DTU to Convert Carbon Into Protein As Part of Bill Gates-Backed Project
Asgard Therapeutics to Unveil AT‑108 Gene Therapy Data at ASGCT 2026
Terremoto Raises $108M to Pursue Development of Drugs Targeting AKT
Adcendo Raises $75M to Advance Cancer Drug Pipeline
Kennedy’s Vaccine Agenda Stalled, Structure’s ‘Competitive’ Obesity Pill, Novo’s Warning Letter
Funding the Future of European Biotech
StockWatch: IPO Market Shows Sign of Life with Avalyn Filing
Cardiometabolic Intervention: Evaluation of PCSK9 Inhibitors as the Successor to the GLP-1 Phenomenon
Business Checking Accounts For DTC Founders: Your Operations Command Center
Recent Deals
MATR Foods Raises €40M in Series A Equity and Venture Debt
Coultreon Biopharma Raises $125M Series A to Advance Novel Immunology Therapy
Alveus Therapeutics Secures $37M Series A Extension Funding
Quantonation Ventures Closes €220M Quantum Fund Backed by Toshiba, Novo Holdings and Others
Terremoto Biosciences Raises $108M in Series C Financing Round
Footprint Fund I Closes €76M Article 9 Deeptech Fund
Expedition Therapeutics Raises $165M Series A Led by Sofinnova Investments and Novo Holdings
Hemab Therapeutics Raises $157M in Series C Led by Sofinnova Partners